Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–8 of 8 results
Advanced filters: Author: Miguel Lopez-Botet Clear advanced filters

  • Monoclonal antibodies (mAbs) that regulate the immune response are now being clinically evaluated as anticancer agents. This Review discusses their progress to date and the possibilities for combining these antibodies with other cancer treatments.

    • Ignacio Melero
    • Sandra Hervas-Stubbs
    • Lieping Chen
    Reviews
    Nature Reviews Cancer
    Volume: 7, P: 95-106

  • Active immunotherapy is emerging as an important addition to conventional cancer treatments, but many important questions remain. Optimal combinations of antigens, adjuvants and delivery vehicles need to be determined and effective strategies for overcoming tumour-associated immunosuppression ought to be developed. This Review provides an overview of new results from clinical studies of therapeutic cancer vaccines directed against tumour-associated antigens and discusses their implications for the use of active immunotherapy.

    • Ignacio Melero
    • Gustav Gaudernack
    • Håkan Mellstedt
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 11, P: 509-524

  • Hepatocellular carcinoma (HCC) is an antigenic lesion infiltrated by T cells, but factors within the tumour and its microenvironment dampen the immune response and prevent effective antitumour immunity. The stepwise elucidation of the various immunosuppressive mechanisms at play in HCC has exposed new therapeutic options. This Review gives a comprehensive overview of the different immunotherapeutic modalities applicable in HCC, including vaccines, adoptive T-cell therapy, cytokines, gene therapy and immune checkpoint inhibitors.

    • Jesús Prieto
    • Ignacio Melero
    • Bruno Sangro
    Reviews
    Nature Reviews Gastroenterology & Hepatology
    Volume: 12, P: 681-700

  • Immunotherapy has undoubtedly become an effective treatment for many cancers, but how can we make the most of this approach? In this Review, Meleroet al. discuss how immune-targeted therapies can be synergistically combined to provide maximal benefit to patients.

    • Ignacio Melero
    • David M. Berman
    • John Haanen
    Reviews
    Nature Reviews Cancer
    Volume: 15, P: 457-472

  • Innate lymphoid cells are important players in the innate immune response, and might also contribute to inflammatory diseases. This Review discusses what is known about these cells and how they might be targeted in future therapies for these diseases.

    • Medya M. Shikhagaie
    • Kristine Germar
    • Hergen Spits
    Reviews
    Nature Reviews Rheumatology
    Volume: 13, P: 164-173